V3020
antibody from NSJ Bioreagents
Targeting: CD59
16.3A5, EJ16, EJ30, EL32, G344, MIC11, MIN1, MIN2, MIN3, MSK21, p18-20
Antibody data
- Antibody Data
- Antigen structure
- References [3]
- Comments [0]
- Validations [0]
Submit
Validation data
Reference
Comment
Report error
- Product number
- V3020 - Provider product page
- Provider
- NSJ Bioreagents
- Product name
- CD59 Antibody
- Antibody type
- Monoclonal
- Antigen
- Stimulated human leukocytes were used as the immunogen for the CD59 antibody.
- Description
- PEG precipitated antibody
- Reactivity
- Human
- Host
- Mouse
- Conjugate
- Unconjugated
- Antibody clone number
- 193-27
- Vial size
- 20 µg, 100 µg (with sodium azide), 100 µg (without sodium azide), 7 ml (prediluted for IHC use, if applicable)
- Storage
- Store the CD59 antibody at 2-8°C (with azide) or aliquot and store at -20°C or colder (without azide).
Submitted references Cell-surface density of complement restriction factors (CD46, CD55, and CD59): oral squamous cell carcinoma versus other solid tumors.
Expression of complement restriction factors (CD46, CD55 & CD59) in head and neck squamous cell carcinomas.
Complement-mediated cell death induced by rituximab in B-cell lymphoproliferative disorders is mediated in vitro by a caspase-independent mechanism involving the generation of reactive oxygen species.
Ravindranath NM, Shuler C
Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics 2007 Feb;103(2):231-9
Oral surgery, oral medicine, oral pathology, oral radiology, and endodontics 2007 Feb;103(2):231-9
Expression of complement restriction factors (CD46, CD55 & CD59) in head and neck squamous cell carcinomas.
Ravindranath NM, Shuler C
Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology 2006 Oct;35(9):560-7
Journal of oral pathology & medicine : official publication of the International Association of Oral Pathologists and the American Academy of Oral Pathology 2006 Oct;35(9):560-7
Complement-mediated cell death induced by rituximab in B-cell lymphoproliferative disorders is mediated in vitro by a caspase-independent mechanism involving the generation of reactive oxygen species.
Bellosillo B, Villamor N, López-Guillermo A, Marcé S, Esteve J, Campo E, Colomer D, Montserrat E
Blood 2001 Nov 1;98(9):2771-7
Blood 2001 Nov 1;98(9):2771-7
No comments: Submit comment
No validations: Submit validation data